RenovoRx Inc. Common Stock is a biotechnology business based in the US. RenovoRx IncCommon Stock shares (RNXT) are listed on the NASDAQ and all prices are listed in US Dollars. RenovoRx IncCommon Stock employs 10 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.60 |
|---|---|
| 52-week range | $3.81 - $16.74 |
| 50-day moving average | $5.67 |
| 200-day moving average | $6.33 |
| Wall St. target price | $15.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.48 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.6 from 2022-01-21
| 1 week (2022-01-14) | -11.33% |
|---|---|
| 1 month (2021-12-23) | -29.27% |
| 3 months (2021-10-22) | -38.78% |
| 6 months (2021-07-20) | N/A |
| 1 year (2021-01-20) | N/A |
|---|---|
| 2 years (2020-01-20) | N/A |
| 3 years (2019-01-20) | N/A |
| 5 years (2017-01-20) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $1.97 |
| Market capitalisation | $35.3 million |
TTM: trailing 12 months
We're not expecting RenovoRx IncCommon Stock to pay a dividend over the next 12 months.
RenovoRx, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California. .
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.